Wednesday
September
02
2015
3:33 am
Weather

  Home
  Local News
  State / National / World
  Sports
  Opinion / Letters
  Business
  Arts / Entertainment
  Lifestyle
  Obituaries
  Calendar
  Submit Event
  Comics / Games
  Classifieds
  DJ Designers
  Archives
  Advertise With Us
  About Us
 
 
 
 
Ex-Genentech worker files lawsuit for firing
August 14, 2012, 05:00 AM By Michelle Durand Daily Journal


Biotech giant Genentech put participants in its human trials for a cancer drug at risk by not following clinical rules and fired a high-level employee who questioned why the company was racing toward the approval deadline, according to a lawsuit filed by the worker who said she was targeted for whistle-blowing.

The suit filed in San Mateo County Superior Court by Juliet Kniley, a former senior clinical program manager at Genentech, alleges she was harassed, demoted and eventually let go after questioning the company’s failure to follow federal guidelines governing clinical trials.

The alleged violations put participants in the clinical trials "at unnecessary risk of death and injury,” according to the suit.

A message from a Genentech representative said she had no immediate knowledge of the suit.

Kniley worked with the Pi3 Kinase program team which was committing "illegal and unethical conduct” by deviating from scientific and ethical standards for human trials, according to her suit.

"This was the first time this drug was being tested in humans so they didn’t know what to expect. What was happening is management was speeding ahead without first waiting for the results of the earlier studies,” said Emily St. John Cohen, one of Kniley’s attorneys.

Kniley had received nothing but excellent reviews and promotions but, after complaining to higher ups about the team’s alleged violations of several laws and safety regulations in the fall of 2008, the suit claims that one doctor in particular verbally harassed and belittled her. Kniley also claims she was excluded from meetings which left her unable to fully function in her job and was twice told that Roche — Genentech’s parent company — would "take this molecule away from us” if it saw the more realistic timelines she presented.

In July and August of 2009, Kniley said she was instructed to let the clinical trial go ahead without the necessary approvals but, after refusing, was demoted and removed from the program.

The downgrade and removal was "pure retaliation” and damaged Kniley’s reputation at the company and in the community, the suit alleges.

Kniley’s performance review for that year was negative, which the suit claims was inaccurate, and she claimed the retaliation — and as a result other poor performance reviews and denial for a new position — continued until her termination Aug. 30, 2011, according to the lawsuit.


Michelle Durand can be reached by email: michelle@smdailyjournal.com or by phone: (650) 344-5200 ext. 102.

 

 

Tags: kniley, clinical, company, according,


Other stories from today:

 

 
Print this Page Print this Page  |  Bookmark and Share
<< Back
 
Return To Archives
 
  


 
 
 
Daily Journal Quick Poll
 
What do you think of the recent White House decision to change the name of Alaska's Mt. McKinley to Denali?

It's good to go back to what most people in Alaska call it
Never thought about it
We should keep the name McKinley
It's OK, but would be nice to find a different way to honor McKinley
How about keeping both names?

 

 
 
 
 
 
 
 
California to end unlimited isolation for most gang leaders
SACRAMENTO — California on Tuesday agreed to end its unlimited isolation of imprisoned gang leader..
Police in Illinois hunt for 3 suspects after officer killed
FOX LAKE, Ill. — Police with helicopters, dogs and armed with rifles were conducting a massive..
US stocks fall sharply on bleak Chinese manufacturing report
NEW YORK — Stocks plunged again Tuesday, continuing a rocky ride for Wall Street, after gloomy eco..
More >>  
 
 
  
 
  
 
©2015 San Mateo Daily Journal
San Mateo County order to show cause